Has Harshad Amin, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,901,233 in general payments to Harshad Amin, MD across 2,657 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Harshad Amin, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Harshad Amin, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Harshad Amin, MD

Hematology & Oncology · Plantation, FLNPI 1679807242

Payments from drug & device makers

$3,901,233in general payments, 2019–2025

Across 2,657 payments — averaging $1468.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Otsuka Pharmaceutical Co., Ltd.$855K
Pfizer$668K
GSK$422K
Karyopharm Therapeutics Inc.$356K
Sanofi US Services Inc.$309K
Eisai Inc.$268K
plus $1M from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Otsuka Pharmaceutical Co., Ltd.	238	$854,628
Pfizer	294	$667,847
GSK	116	$422,088
Karyopharm Therapeutics Inc.	38	$355,772
Sanofi US Services Inc.	39	$309,048
Eisai Inc.	183	$267,710
Amgen	33	$246,800
Taiho Oncology, Inc.	54	$119,529
Exelixis Inc.	40	$102,412
Merck	82	$85,887
Mirati Therapeutics, Inc.	26	$83,207
Gilead	15	$80,125
Lilly USA, LLC	142	$68,147
Tolmar, Inc.	37	$65,930
Immunomedics, Inc.	1	$37,923
Napo Pharmaceuticals Inc	5	$29,500
Genentech, Inc.	2	$27,800
Bristol Myers Squibb	70	$15,177
Global Blood Therapeutics, Inc.	9	$9,545
Bayer	34	$7,668
Acceleron Pharma, Inc.	5	$7,430
Jazz Pharmaceuticals Inc.	20	$4,270
Eli Lilly Export S.A. Puerto Rico Branch	4	$3,415
AstraZeneca(2 entities)	146	$3,367
Johnson & Johnson(2 entities)	91	$3,103
E.r. Squibb & Sons, L.L.C.	150	$2,754
Ipsen Biopharmaceuticals, Inc	16	$2,501
Genentech USA, Inc.	144	$1,972
Dova Pharmaceuticals	12	$1,896
Novartis	110	$1,811
Rigel Pharmaceuticals, Inc.	35	$1,627
Sanofi	43	$1,507
Seagen Inc.	58	$1,142
Incyte Corporation	46	$888
AbbVie	33	$622
Astellas Pharma US Inc	27	$537
Daiichi Sankyo Inc.	27	$453
Puma Biotechnology, Inc.	25	$427
Array Biopharma Inc	20	$380
Takeda Pharmaceuticals U.S.A., Inc.	17	$378
AVEO Pharmaceuticals, Inc.	9	$305
Deciphera Pharmaceuticals Inc.	13	$297
Foundation Medicine, Inc.	12	$260
Pharmacyclics LLC, An Abbvie Company	8	$238
Regeneron Healthcare Solutions, Inc.	9	$225
Boehringer Ingelheim	9	$213
Novocure GmbH	1	$200
Pharmacosmos Therapeutics Inc.	9	$190
Athenex Pharmaceutical Division, LLC	1	$175
EMD Serono, Inc.	9	$144
Adaptive Biotechnologies Corporation	6	$141
Servier Pharmaceuticals LLC	7	$133
Sirtex Medical Inc	6	$117
Beigene USA, Inc.	6	$109
Myovant Sciences Inc.	5	$96
TG Therapeutics, Inc.	4	$84
Sobi, Inc	5	$83
Kyowa Kirin, Inc.	3	$81
Alnylam Pharmaceuticals Inc.	3	$76
Beone Medicines USA, Inc.	3	$68

How this compares

$3,901,233 in reported general payments places this provider in the 95th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida →

Medicare billing

Part B allowed, 2024

$4,305,914

Medicare patients

455

Services billed

149,017

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Plantation

Carl LandgrenMiami$47.8M
Julio ChavezTampa$16.4M
Steven AttiaJacksonville$13.9M
Santosh NairOrange City$13.5M
Frederick LockeTampa$12.8M
Tarek MekhailOrlando$11.2M
Carlos AlemanyOrlando$10.9M
Thomas GeorgeGainesville$10.3M
Sikander AilawadhiJacksonville$9.8M
Richard KimTampa$8.5M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →